REVIVE Blend Side Effects: What Is Reported, What to Report, and Who Should Avoid It

There are no placebo-controlled rates for REVIVE side effects, so this page gives descriptions, not percentages.

REVIVE is four peptides dissolved together in one 5 mL vial: 50 mg GHK-Cu, 6 mg CJC-1295, 12 mg ipamorelin and 2 mg TB-500. Pepti's typical directions are 0.25 mL, which is 25 units on a U-100 insulin syringe, under the skin Monday through Friday nights at bedtime, so each dose delivers 2.5 mg GHK-Cu, 0.3 mg CJC-1295, 0.6 mg ipamorelin and 0.1 mg TB-500. Your physician sets your directions after reviewing your intake, and they are printed on the vial. REVIVE is $279 a month, all-in. Dosing detail is in REVIVE blend dosage.

So REVIVE's side effects come in two families: the growth hormone half and the copper-carrying repair half. There is no side-effect data for the four together, because the blend has never been studied as a blend. The component detail is in is CJC-1295 / Ipamorelin safe, is GHK-Cu safe and is TB-500 safe.

CJC-1295 and ipamorelin prompt your own pituitary to release growth hormone in pulses. Nothing in the vial is the hormone itself, and the 2006 human studies of CJC-1295 reported the pituitary's pulsatile pattern being preserved. But a larger pulse has the same family of effects as growth hormone, and the pattern is recognisable:

Blood sugar

Growth hormone is counter-regulatory to insulin, so sustained increases reduce insulin sensitivity and can raise fasting glucose. The closest long-duration human data in the class comes from a different compound, an oral ghrelin mimetic given daily to healthy adults aged 60 to 81 for one to two years in a 2008 Annals of Internal Medicine trial, which reported fasting glucose rising by an average of 5 mg/dL and insulin sensitivity falling. In practice, diabetes or impaired glucose tolerance is raised at intake and means closer attention rather than an automatic no. Anyone on insulin or a sulfonylurea who has shakiness, sweating or confusion should treat the low blood sugar, then report it the same day.

This is the part of REVIVE's safety picture that separates it from the two-peptide CJC-1295 / Ipamorelin vial. Copper is essential in small amounts and harmful in excess, and the liver is the body's route for excreting it.

This pattern is not reported at prescribed GHK-Cu doses in people with normal copper handling. It belongs to identifiable people: anyone with Wilson's disease, anyone whose liver cannot excrete copper normally, and anyone unknowingly taking two copper-containing products at once. Every GHK-Cu blend carries a full GHK-Cu dose, so REVIVE alongside standalone GHK-Cu, GLOW or KLOW doubles the copper. High-dose zinc competes with copper absorption, so your physician needs to know your zinc dose too. Do not change your supplements on your own in either direction; tell your physician what you take.

Two separate reasons put a cancer history on the intake. Growth hormone and IGF-1 are growth signals; no evidence shows them causing cancer, but a tissue that is already malignant can respond to growth signals. And GHK-Cu and TB-500 are described in cell and animal work as supporting new blood-vessel growth, and thymosin beta-4, the parent of TB-500, as promoting cell migration, which are processes a healing tissue needs and a growing tumour also uses. There is no human evidence that any component causes or accelerates cancer. A physician will decline REVIVE with an active cancer, and a cancer in remission is a cautious conversation that includes your oncologist. See can peptides cause cancer.

If you think you may have taken too much, for example by drawing the wrong amount, call Poison Control at 1-800-222-1222 and message your care team. Do not skip, double or change a dose to compensate.

Not every side effect is urgent. Message your care team through your account for:

• Injection-site reactions that keep happening despite rotating sites.
• Puffiness, joint aches or tingling hands, even if mild.
• Headache, light-headedness or tiredness that has not settled after the first couple of weeks.
• A metallic taste, or nausea that seems to follow each dose.
• Any change in your medications or supplements, especially glucose-lowering medication, blood thinners, testosterone, zinc, or another GHK-Cu product.
• A new diagnosis, a pregnancy, or a planned surgery.

Your physician may revise your directions, change the product, or stop treatment. Do not change the dose yourself. When directions change, the new numbers are printed on the new label. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

There is no established interaction list for REVIVE or any component, because the trials that would produce one have not been run. Two combinations are worth naming: anything that lowers blood glucose, and testosterone, where growth hormone and testosterone have additive effects on the side-effect pattern.

• Side effects of the four together. REVIVE has never been studied as a combination, in people or in animals.
• Long-term human outcomes. No cohort has been followed for years on REVIVE or any component by injection.
• Subcutaneous data. There are no human data for subcutaneous ipamorelin, the 2006 trials used the long-acting DAC form of CJC-1295 rather than the form in the vial, and TB-500 has no human trials at all.
• Whether the theoretical cancer concern is real. It is mechanistic reasoning, not an observed human signal, and it has not been ruled out.
• Immunogenicity rates. No study has measured how often any component produces antibodies.

Each component is generally described as well tolerated in its own published work, and clinical reports on the blend are consistent with that: mostly injection-site reactions, with the flushing, headache and hunger of the secretagogue half. The 2006 CJC-1295 trials in healthy adults described it as well tolerated, and the two human ipamorelin studies, a 1999 volunteer study and a seven-day surgical trial, did the same. GHK-Cu's human data is mostly topical; TB-500 has none.

So the honest statement is narrow: short-term tolerability looks good where REVIVE's components have been used, there is a recognisable pattern when the growth hormone signal is larger than a person needs, and long-term safety is not characterised. The separate and non-theoretical risk is supply: research-use-only blends are sold openly with no pharmacy accountable for identity, purity, sterility or concentration. The distinction is set out in research peptides vs prescription peptides.

Where the components stand with the FDA: none is currently in 503A Category 2. TB-500 was recommended for the 503A Bulks List by the advisory committee in July 2026, with the final determination pending; GHK-Cu is scheduled for review before the end of February 2027; the committee voted against CJC-1295 and ipamorelin in late 2024 for the uses it examined, with no final FDA rule for either. Compounded medications are not FDA approved, and REVIVE is not an FDA-approved drug.

REVIVE cannot be bought legitimately without a prescription. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with ice packs, with sterile syringes, alcohol prep pads and your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

REVIVE is $279 a month, all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Refills run every 28 days, one vial per fill. The full reference is what is REVIVE, and the secretagogue half on its own is covered in ipamorelin side effects.